HUTCHMED (China) (HCM) vs Prestige Consumer Healthcare (PBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
HUTCHMED (China) (HCM) has outperformed Prestige Consumer Healthcare (PBH) over the past year, losing 12.0% versus a loss of 23.2%. Over five years, PBH leads with a -17.4% price change compared with -56.3% for HCM. HUTCHMED (China) is the larger company by market cap ($2.45 billion vs $2.28 billion), about 1.1 times the size, while Prestige Consumer Healthcare is growing revenue faster (-4.3% vs -13.0%).
On valuation, Prestige Consumer Healthcare trades at a lower forward P/E (9.5x vs 54.4x for HUTCHMED (China)). HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus 17.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | PBH |
|---|---|---|
| Share price | $14.10 | $48.23 |
| Market cap | $2.45B | $2.28B |
| 1-day change | +3.15% | +0.75% |
| YTD return | +5.78% | -21.82% |
| 1-year return | -11.99% | -23.19% |
| 5-year return | -56.35% | -17.44% |
| P/E ratio (TTM) | 141.00 | 13.51 |
| Forward P/E | 54.40 | 9.49 |
| EPS (TTM) | $0.10 | $3.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | $1.09B |
| Revenue growth (YoY) | -12.96% | -4.31% |
| Net income (latest FY) | $456.91M | $190.30M |
| Gross margin | 38.68% | 54.71% |
| Operating margin | -7.14% | 28.42% |
| Net margin | 83.30% | 17.48% |
| 52-week high | $16.33 | $71.07 |
| 52-week low | $9.77 | $42.62 |
| Distance from 52-week high | -13.66% | -32.14% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +56.10% | +40.58% |
| Average volume | 68.02K | 547.31K |
| Shares outstanding | 173.81M | 47.37M |
| Employees | 1,790 | 890 |
| Sector | Healthcare | Health Care |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HCM has outperformed PBH by 11.2 percentage points over the past year.
- HUTCHMED (China) trades at a higher earnings multiple (141.0x vs 13.5x trailing P/E).
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus 17.5 cents for Prestige Consumer Healthcare.
- Prestige Consumer Healthcare grew revenue faster in its latest fiscal year (-4.31% vs -12.96%).
- The two companies sit in different sectors: HUTCHMED (China) in Healthcare and Prestige Consumer Healthcare in Health Care.
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,790 employees
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
HCM vs PBH FAQ
Which is bigger, HUTCHMED (China) or Prestige Consumer Healthcare?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.45B compared with $2.28B for Prestige Consumer Healthcare (PBH).
Which stock has performed better over the past year, HCM or PBH?
HCM returned -11.99% over the past 12 months, compared with -23.19% for PBH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HCM or PBH?
PBH has the lower trailing P/E at 13.5, versus 141.0 for HCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are HUTCHMED (China) and Prestige Consumer Healthcare in the same industry?
No. HUTCHMED (China) is in the Healthcare sector, while Prestige Consumer Healthcare is in Health Care.